reboxetine has been researched along with rx 821002 in 2 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (rx 821002) | Trials (rx 821002) | Recent Studies (post-2010) (rx 821002) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 317 | 0 | 45 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, ST; Chuang, CH; Kao, YC; Lin, YL; Liu, YP; Tung, CS | 1 |
| Artigas, F; Bortolozzi, A; Masana, M | 1 |
2 other study(ies) available for reboxetine and rx 821002
| Article | Year |
|---|---|
Alpha adrenergic modulation on effects of norepinephrine transporter inhibitor reboxetine in five-choice serial reaction time task.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Attention; Discrimination, Psychological; Drug Evaluation, Preclinical; Drug Interactions; Feeding Behavior; Idazoxan; Impulsive Behavior; Male; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Prazosin; Rats; Rats, Sprague-Dawley; Reaction Time; Reboxetine; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Spatial Behavior; Time Perception | 2009 |
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electric Stimulation; Haloperidol; Idazoxan; Male; Microdialysis; Molecular Targeted Therapy; Morpholines; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Wistar; Reboxetine; Schizophrenia; Synaptic Transmission; Ventral Tegmental Area | 2011 |